Eli Lilly led the sector's gains, with shares climbing more than 5% following a 39% jump in quarterly revenue. This growth was fueled by heavy demand for its Mounjaro and Zepbound medications. Merck also saw its stock rise sharply after reporting a 5% increase in sales, buoyed by the continued success of its flagship cancer drug Keytruda and the newer therapy Winrevair.

Bristol Myers Squibb joined the upward trend, seeing share prices tick higher after the company adjusted its 2026 revenue projections upward. The positive sentiment underscores a period of sustained profitability for the industry, as pharmaceutical giants lean into high-performing portfolios to drive shareholder value.